Novartis AG Sponsored ADR (NVS)
Syngenta acquires genetic repository from Novartis to boost biologic crop protection
Switzerland-based pesticides maker Syngenta said on Wednesday that it has acquired a repository of natural compounds and genetic strains from drugmaker Novartis to further boost development of biologic crop protection.
Here's Why Novartis (NVS) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novartis Invests $7.5M to Promote Early Prostate Cancer Testing in Vulnerable Communities
Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for prostate cancer in vulnerable communities.
Novartis: Strong Execution With A P/E Discount
Q4 2024 results exceeded expectations with 16% net sales growth and a 55% increase in operating income, supporting Novartis' EPS growth trajectory. The acquisition of Anthos Therapeutics and strategic investments in R&D confirmed our thesis on Novartis' new pure play as an innovative medicines leader. Novartis' strong FCF generation, supportive dividend yield, and ongoing buyback make it a buy. The company also trades below its peer average multiple.
Novartis: Just What The Doctor Ordered
Novartis' robust drug pipeline and strong financials, including an AA- credit rating, support an 11% annual return expectation by 2027. The company's diverse blockbuster portfolio and strategic cost management drove a 15.1% sales increase and 29% EPS growth in Q4 2024. Novartis' shares are undervalued by 11%, offering a 33% cumulative return potential through 2027, with a secure and growing 3.5% dividend yield.
Novartis to buy Anthos Therapeutics in $3.1bn deal
Novartis AG (ADR) (NYSE:NVS) has agreed to buy Anthos Therapeutics in a deal worth up to $3.1 billion. The Swiss drugmaker will pay $925 million upfront, with potential milestone payments of $2.15 billion.
Novartis agrees to acquire Anthos for up to $3.1 bln
Novartis has agreed to acquire Anthos Therapeutics, a developer of a new generation of blood thinners it launched five years ago with backing from the Swiss pharmaceutical giant.
Novartis Rises 5% Since Q4 Earnings: How Should You Play the Stock?
NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors already owning the stock can stay invested.
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Novartis (NVS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Novartis is considering further acquisitions to drive growth, CEO says
Novartis CEO Vas Narasimhan weighs in on the impact of the new U.S. administration and artificial intelligence on the pharmaceutical industry, as well as the possibility of further acquisitions.
Novartis Posts Q4 Earnings and Sales Beat, Shares Gain
NVS' fourth-quarter earnings and sales beat estimates. Based on the strong momentum of the company?
